HC Wainwright Issues Negative Outlook for ACTU Earnings

Key Points

• HC Wainwright has revised its Q3 2025 EPS estimate for Actuate Therapeutics down to ($0.25), from a previous estimate of ($0.18), while maintaining a "Buy" rating and a $20.00 price target for the stock.
• Actuate Therapeutics' shares have recently declined 3.4% and are trading at $7.97, with a one-year price range from $5.47 to $11.99.
• Insider transactions show significant activity, as Director Aaron G.L. Fletcher purchased 71,428 shares at $7.00 each, increasing his position by 57.14%.

Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) - Equities researchers at HC Wainwright lowered their Q3 2025 earnings estimates for shares of Actuate Therapeutics in a report issued on Monday, August 18th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.25) per share for the quarter, down from their previous forecast of ($0.18). HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock. HC Wainwright also issued estimates for Actuate Therapeutics' Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.05) EPS and FY2026 earnings at ($1.02) EPS.

Separately, Wall Street Zen downgraded shares of Actuate Therapeutics from a "hold" rating to a "sell" rating in a report on Friday. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Actuate Therapeutics currently has a consensus rating of "Buy" and an average price target of $20.50.

Actuate Therapeutics Stock Performance

Shares of Actuate Therapeutics stock traded up $0.70 during trading hours on Wednesday, reaching $8.36. The company's stock had a trading volume of 58,818 shares, compared to its average volume of 64,528. The firm has a 50 day moving average price of $7.05 and a 200-day moving average price of $7.93. Actuate Therapeutics has a one year low of $5.47 and a one year high of $11.99.

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.11).

Insider Activity at Actuate Therapeutics

In other news, Director Equity Cof Lp Bios purchased 71,428 shares of the business's stock in a transaction that occurred on Friday, June 27th. The shares were bought at an average cost of $7.00 per share, for a total transaction of $499,996.00. Following the acquisition, the director owned 196,428 shares of the company's stock, valued at approximately $1,374,996. This trade represents a 57.14% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Aaron G.L. Fletcher purchased 71,428 shares of the business's stock in a transaction that occurred on Friday, June 27th. The shares were purchased at an average price of $7.00 per share, for a total transaction of $499,996.00. Following the completion of the acquisition, the director directly owned 196,428 shares in the company, valued at $1,374,996. The trade was a 57.14% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 214,284 shares of company stock worth $1,499,988. Insiders own 69.34% of the company's stock.

Hedge Funds Weigh In On Actuate Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Sfmg LLC grew its holdings in Actuate Therapeutics by 32.3% during the 2nd quarter. Sfmg LLC now owns 14,550 shares of the company's stock valued at $89,000 after purchasing an additional 3,550 shares during the last quarter. Sigma Planning Corp grew its holdings in Actuate Therapeutics by 47.3% during the 1st quarter. Sigma Planning Corp now owns 23,675 shares of the company's stock valued at $160,000 after purchasing an additional 7,600 shares during the last quarter. Chicago Partners Investment Group LLC bought a new position in Actuate Therapeutics during the 1st quarter valued at about $70,000. Envestnet Asset Management Inc. bought a new position in Actuate Therapeutics during the 4th quarter valued at about $83,000. Finally, OMERS ADMINISTRATION Corp bought a new position in Actuate Therapeutics during the 4th quarter valued at about $84,000.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.